Showing results (11-20 of 23) with videos related to
Sort By:
Pageof 3
Nucleic Acids Research|February 26, 2004
The DNA-binding properties of the ARID-containing subunits of yeast and mammalian SWI/SNF complexesDeborah Wilsker, Antonia Patsialou, Steven D Zumbrun, et al.The Biochemical Journal|June 2, 2004
Two related ARID family proteins are alternative subunits of human SWI/SNF complexesXiaomei Wang, Norman G Nagl, Deborah Wilsker, et al.Oncotargets and Therapy|March 3, 2022
PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway ComponentsGeraldine O'Sullivan Coyne, Chris Karlovich, Deborah Wilsker, et al.Epigenetics|February 19, 2024
Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitorsJulia Krushkal, Yingdong Zhao, Kyle Roney, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2015
Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid TumorsKhanh Do, Deborah Wilsker, Jiuping Ji, et al.Biology of Reproduction|January 16, 2004
Expression of genes encoding chromatin regulatory factors in developing rhesus monkey oocytes and preimplantation stage embryos: possible roles in genome activationPing Zheng, Bela Patel, Malgorzata McMenamin, et al.Oncotarget|April 24, 2018
Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug-induced DNA double strand breaks from DNA double strand breaks associated with apoptosisAngie B Dull, Deborah Wilsker, Melinda Hollingshead, et al.Cancer Research|April 28, 2017
The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic ActivitySusan L Holbeck, Richard Camalier, James A Crowell, et al.Cancer Chemotherapy and Pharmacology|November 27, 2023
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumorsArjun Mittra, Geraldine H O' Sullivan Coyne, Jennifer Zlott, et al.JCO Precision Oncology|July 16, 2025
Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid TumorsGeraldine O'Sullivan Coyne, Khanh T Do, Shivaani Kummar, et al.Pageof 3